C4X-6746 / C4X Discovery, AstraZeneca - LARVOL DELTA

C4X Discovery in advanced discussions to out-license third drug programme (Proactiveinvestors) - "C4X Discovery Holdings PLC...said it is in 'advanced commercial discussions with multiple potential partners' for its NRF2 activator programme for inflammatory diseases....In the update, which accompanied the company’s prelims, C4X said it was also looking for partners for its inflammatory bowel disease candidate..."

Licensing / partnership • Immunology • Inflammatory Bowel Disease

[VIRTUAL] Efficacy of a novel non-covalent oral small molecule Nrf2 activator in a rat model of Inflammatory Bowel Disease (ECCO-IBD 2021) - "Efficacy of C4X_6746 in the model correlated with the dose-dependent induction of NQO1 mRNA in the colon and blood as a biomarker for Nrf2 pathway activation. Conclusion The efficacy of C4X_6746 in the rat DSS model supports development of non-covalent oral Nrf2 activators to significantly reduce oxidative tissue damage and chronic inflammation in IBD."

Preclinical • Immunology • Inflammation • Inflammatory Bowel Disease • KEAP1 • NQO1